Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXYAIQ)

Drug Name

(E)-Octadec-9-enal Drug Info

Synonyms

9-OCTADECENAL; Octadecenyl aldehyde; (E)-Octadec-9-enal; UNII-979G27P46D; CHEMBL190707; 979G27P46D; 9-Octadecenal, (9E)-; 5090-41-5; E-9-Octadecenal; 9-Octadecenal, (E)-; FEMA No. 4059, E-; 10009-79-7; (9E)-9-Octadecenal; (9E)-9-Octadecenal #; AC1NR25P; SCHEMBL260834; DTXSID9074305; ZENZJGDPWWLORF-MDZDMXLPSA-N; MolPort-044-723-520; LMFA06000099; BDBM50170061; UNII-971UC454BB component ZENZJGDPWWLORF-MDZDMXLPSA-N

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5283381
CAS Number: CAS 5090-41-5
TTD Drug ID: DMXYAIQ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Transient receptor potential cation channel V1 (TRPV1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[2]
CNTX-4975	DMB4JPG	Knee osteoarthritis	FA01	Phase 3	[3]
XEN-D0501	DMG7PDY	Overactive bladder	GC50.0	Phase 2	[4]
Resiniferatoxin	DMP62L5	Neuropathic pain	8E43.0	Phase 2	[5]
PAC-14028	DM3816P	Atopic dermatitis	EA80	Phase 2	[6]
GRC-15300	DMWXJSZ	Pain	MG30-MG3Z	Phase 2	[7]
DWP-05195	DMQKU2F	Neuropathic pain	8E43.0	Phase 2	[8]
SB-705498	DMRYHWI	Rhinitis	FA20	Phase 2	[9]
GRC-6211	DMZ0D3V	Asthma	CA23	Phase 1	[10]
ABT-102	DMJFWPR	Chronic pain	MG30	Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transient receptor potential cation channel V1 (TRPV1)	TTMI6F5	TRPV1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic iodination. J Med Chem. 2005 Jul 14;48(14):4663-9.
2	Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921-31.
5	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
6	Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6.
7	The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest. 2010 November 1; 120(11): 3753-3759.
8	TRPV1 Antagonists as Analgesic Agents. The Open Pain Journal, 2013, 6, (Suppl 1: M11), 108-118 .
9	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
10	GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol. 2009 Jan;181(1):379-86.